logo

For the Inventor, By the Inventor

Collegeville, PA, United States of America

Sylvie Laquerre

This inventor holds 6 USPTO granted patents and 4 published patent applications and 10 EPO patents. Top assignees: Glaxosmithkline LLC, Novartis Ag. Active years: 2014-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sylvie Laquerre. Retrieved from https://idiyas.com/inventor/sylvie-laquerre-vxc956y1

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 

% Patents Active = 50.0

 

Average Co-Inventor Count = 4.0

ph-index = 3

Forward Citations = 34(Granted Patents)


Location History:

  • Collegeville, PA (US) (2014 - 2015)
  • King of Prussia, PA (US) (2016 - 2020)

Company Filing History:

goldMedal4 out of 358 
 
Glaxosmithkline LLC
 patents
silverMedal2 out of 3,977 
 
Novartis Ag
 patents

Years Active: 2014-2020

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents
1. 10869869 - Method of adjuvant cancer treatment (2020-12-22),
2. 9402846 - Combination of inhibitor of B-Raf and inhibitor of AKT in the treatment of cancer (2016-08-02),
3. 8952018 - Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors (2015-02-10),
4. 8835450 - Combination of inhibitor of B-Raf and an inhibitor of Akt in the treatment of cancer (2014-09-16),
5. 8796298 - Combination of a B-Raf inhibitor: N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1- dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide and the Akt inhibitor: N-{ (1S)-2-amino-1-[(3- fluorophenyl)methyl]ethyl}-5-chIoro-4-(4-chIoro- 1 -methyl- 1 H-pyrazol-5-yl)-2-10 thiophenecarboxamide useful in the treatment of cancer (2014-08-05),
6. 8703781 - Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors (2014-04-22),

Title: Sylvie Laquerre: Innovator in Cancer Treatment

Introduction

Sylvie Laquerre is a prominent inventor based in Collegeville, PA (US), known for her significant contributions to cancer treatment. With a total of 6 patents, she has developed innovative methods that aim to improve patient outcomes in oncology.

Latest Patents

One of her latest patents is titled "Method of adjuvant cancer treatment." This invention provides a method of administering therapeutically effective doses of dabrafenib and trametinib to human patients, which is designed to increase relapse-free survival (RFS). Another notable patent is "Combination of inhibitor of B-Raf and inhibitor of AKT in the treatment of cancer." This invention relates to a method of treating cancer in humans using specific pharmaceutical combinations that include N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide and N-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide.

Career Highlights

Throughout her career, Sylvie has worked with leading pharmaceutical companies, including GlaxoSmithKline LLC and Novartis AG. Her work has focused on developing effective treatments that address critical needs in cancer therapy.

Collaborations

Sylvie has collaborated with notable professionals in her field, including Peter F. Lebowitz and Rakesh Kumar. These collaborations have contributed to her innovative approaches in cancer treatment.

Conclusion

Sylvie Laquerre's work in cancer treatment exemplifies her dedication to improving patient care through innovation. Her patents reflect her commitment to advancing medical science and providing effective solutions for cancer patients.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…